KPRX

Kiora Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.930

-0.06(-2.007%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.0599

Open

2.990

VWAP

Vol

20.68K

Mkt Cap

8.92M

Low

2.8994

Amount

EV/EBITDA(TTM)

Total Shares

2.92M

-15.19M

EV/OCF(TTM)

P/S(TTM)

615.01

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

750.00K

-95.31%

Estimates Revision

The market is revising Downward the revenue expectations for Kiora Pharmaceuticals, Inc. (KPRX) for FY2025, with the revenue forecasts being adjusted by -50% over the past three months. During the same period, the stock price has changed by -10.90%.

Revenue Estimates for FY2025

Revise Downward

-50%

In Past 3 Month

Stock Price

Go Down

-10.90%

In Past 3 Month

2 Analyst Rating

275.43% Upside

Wall Street analysts forecast KPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPRX is 11.00 USD with a low forecast of 10.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

275.43% Upside

Current: 2.930

Low

10.00

Averages

11.00

High

12.00

275.43% Upside

Current: 2.930

Low

10.00

Averages

11.00

High

12.00

H.C. Wainwright

Buy

maintain

$10

2025-07-22

Reason

H.C. Wainwright

Price Target

$10

2025-07-22

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating and $10 price target on shares of Kiora Pharmaceuticals after the company announced that it received received a U.S. patent covering KIO-104 for the treatment of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. The patent covers varying dosing schedules, necessary excipients, and other novel methods for optimizing treatment of ocular inflammatory diseases, the analyst tells investors in a research note. The new patent should strengthen the company's IP portfolio and help secure the potential market prospects if KIO-104 is successfully developed in clinical studies, the firm says.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$10

2025-03-28

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2025-03-28

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$10

2024-11-12

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2024-11-12

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$10

2024-08-22

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2024-08-22

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Kiora Pharmaceuticals Inc (KPRX.O) is -1.36, compared to its 5-year average forward P/E of -1.26. For a more detailed relative valuation and DCF analysis to assess Kiora Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.26

Current PE

-1.36

Overvalued PE

0.74

Undervalued PE

-3.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.38

Current PS

3.03

Overvalued PS

13.01

Undervalued PS

-4.24